Sanuwave On Track To Submit dermaPACE PMA By June 30
This article was originally published in The Gray Sheet
Executive Summary
Sanuwave Health says it is on track to wrap up a PMA submission by the end of June for its dermaPACE wound care device, which treats chronic diabetic foot ulcers with high-energy acoustic pressure waves.
You may also be interested in...
Sanuwave Completes Modular PMA For Diabetic Foot Ulcer Treatment
Sanuwave Health completed a modular PMA application for its dermaPACE diabetic foot ulcer treatment with the submission of pivotal trial data, announced July 6.
Sanuwave Completes Modular PMA For Diabetic Foot Ulcer Treatment
Sanuwave Health completed a modular PMA application for its dermaPACE diabetic foot ulcer treatment with the submission of pivotal trial data, announced July 6.
Shire Nabs Advanced BioHealing Just Prior To Planned IPO
Just before its planned debut on the New York Stock Exchange, wound healing device maker Advanced BioHealing Inc. instead agreed to a $750 million buyout offer May 17 from drug maker Shire PLC, which has a history of using acquisitions to jump quickly into new lines of business.